Skip to content

RheumAFooT (Rheumatoid Arthritis Foot Trial)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN01982076
Enrollment
34
Registered
2003-08-18
Start date
2003-10-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis Musculoskeletal Diseases Rheumatoid arthritis

Interventions

Active treatment arm: 12 months podiatry care Control treatment arm: 12 months

Sponsors

Medical Research Council (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients will be suitable for inclusion if they have a definite diagnosis of RA (satisfying the 1987 American Rheumatism Association revised criteria for RA), are between 18-80 years of age and can read and write English. Patients must also have a current history of foot impairment as determined by standard history and clinical examination techniques and a Leeds Foot Impact Scale score of =15 points. Patients must also have stable drug management in the 3 months prior to recruitment including Disease Modifying Anti-Rheumatic Drugs, Non-Steroidal Anti-Inflammatory Drugs and oral corticosteroids.

Exclusion criteria

Exclusion criteria: Patients will be excluded if they have foot problems related to and require treatment under the appropriate medical specialty such as diabetes and peripheral vascular disease. Patients will be excluded if they have severe complications of their RA resulting in active or high risk of developing foot ulceration. On medical consultation, any patient with foot problems, such as ulceration and infection, likely to complicate systematic treatment with biologic and other immunosuppressant therapy (Infliximab, Etanercept, Anakinra, Cyclophosphamide, Cyclosporin, Azathioprine and any new, including trial, biologic - even if placebo) will be excluded. Those patients who have received podiatry treatment at Leeds General Infirmary Foot Health Department in the last 3 months will also be excluded.

Design outcomes

Primary

MeasureTime frame
Primary outcome: change in Leeds Foot Impact Scale score between baseline and 12 months.

Secondary

MeasureTime frame
Disease activity score, health assessment questionnaire and walking speed were also recorded.

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026